Kwangdong Pharmaceutical광동제약

Kwangdong Pharmaceutical reports thin margins and flat recent profits, while its share price has risen over the past year.

Kwangdong Pharmaceutical is a Korean pharma and beverage company with trailing revenue of about ₩1.7T and a small operating margin of 2%. Net income over the last twelve months is about ₩22B, below the ₩40B booked in 2024, and the company carries ₩304B of borrowings against ₩87B of cash. The shares closed at ₩6,590 on 23 October 2026, up 14.4% over one year but well below their 52-week high of ₩12,800.

What stands out

• Revenue rose from ₩1.51T in 2023 to ₩1.66T in 2025, but operating margin has slipped from 2.8% to 1.9% over the same period.
• 2024 net income of ₩40B was higher than 2025's ₩21B, so 2025 earnings were weaker than the prior year's headline figure.
• The data shows a DCF-based fair value of ₩8,504 against the ₩6,590 close, but the bear and bull cases are very far apart, so this range is highly sensitive to assumptions.
• Valuation metrics are modest: P/E about 15, P/B about 0.5, dividend yield 1.5%, while peers such as Samsung Biologics and Celltrion trade at much higher multiples.
• Recent headlines centre on controversy over Chimhyang pill pricing and advertising, which the Ministry of Food and Drug Safety has referred to police for sellers.
• Recent filings include several 5%+ holding reports and a change in the largest shareholder's holdings, and foreign ownership eased from 16.5% to 15.9% over about 60 days.

What to watch

• The next quarterly results and whether margins recover from the current 2% operating level.
• Any follow-up from regulators or police on Chimhyang advertising, and whether it affects sales or brand reputation.
• Further changes in the largest shareholder's stake and the 5%+ holding reports, which the filings do not explain in detail.